Michael A. James, PhD

Publications

• CLPTM1L/CRR9 ectodomain interaction with GRP78 at the cell surface signals for survival and chemoresistance upon ER stress in pancreatic adenocarcinoma cells.

  (Clarke WR, Amundadottir L, James MA.) Int J Cancer. 2019 Mar 15;144(6):1367-1378.

• Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models.

  (Tsai S, McOlash L, Palen K, Johnson B, Duris C, Yang Q, Dwinell MB, Hunt B, Evans DB, Gershan J, James MA.) BMC Cancer. 2018 03 27;18(1):335.

• Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.

  (Bodle CR, Mackie DI, Hayes MP, Schamp JH, Miller MR, Henry MD, Doorn JA, Houtman JCD, James MA, Roman DL.) J Nat Prod. 2017 07 28;80(7):1992-2000.

• Stromal Inflammation in Pancreatic Cancer: Mechanisms and Translational Applications

  (Boyle K, James MA, Tsai S, Evans DB, Dwinell MB..) Pancreatic Cancer. 2nd Ed. Springer-Verlag New York. DOI: 10.1007/978-1-4939-6631-8_55-1.

• Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling.

  (Puskás LG, Mán I, Szebeni G, Tiszlavicz L, Tsai S, James MA.) Mol Cancer Ther. 2016 05;15(5):985-97.

• Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.

  (Lee Y, Wang Y, James M, Jeong JH, You M.) Mol Carcinog. 2016 May;55(5):991-1001.

• Functional characterization of RAD52 as a lung cancer susceptibility gene in the 12p13.33 locus.

  (Lieberman R, Xiong D, James M, Han Y, Amos CI, Wang L, You M.) Mol Carcinog. 2016 May;55(5):953-63.

• A novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression.

  (James MA, Seibel WL, Kupert E, Hu XX, Potharla VY, Anderson MW.) Anticancer Drugs. 2015 Jun;26(5):518-30.

• CRR9/CLPTM1L regulates cell survival signaling and is required for Ras transformation and lung tumorigenesis.

  (James MA, Vikis HG, Tate E, Rymaszewski AL, You M.) Cancer Res. 2014 Feb 15;74(4):1116-27.

• Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus.

  (James MA, Wen W, Wang Y, Byers LA, Heymach JV, Coombes KR, Girard L, Minna J, You M.) PLoS One. 2012;7(6):e36116.

• Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing.

  (Liu P, Morrison C, Wang L, Xiong D, Vedell P, Cui P, Hua X, Ding F, Lu Y, James M, Ebben JD, Xu H, Adjei AA, Head K, Andrae JW, Tschannen MR, Jacob H, Pan J, Zhang Q, Van den Bergh F, Xiao H, Lo KC, Patel J, Richmond T, Watt MA, Albert T, Selzer R, Anderson M, Wang J, Wang Y, Starnes S, Yang P, You M.) Carcinogenesis. 2012 Jul;33(7):1270-6.

• Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer.

  (Lu Y, Liu P, Van den Bergh F, Zellmer V, James M, Wen W, Grubbs CJ, Lubet RA, You M.) Cancer Prev Res (Phila). 2012 Feb;5(2):248-59.